Dung T. Le

48.7k total citations · 9 hit papers
197 papers, 11.2k citations indexed

About

Dung T. Le is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, Dung T. Le has authored 197 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 173 papers in Oncology, 50 papers in Pathology and Forensic Medicine and 38 papers in Cancer Research. Recurrent topics in Dung T. Le's work include Cancer Immunotherapy and Biomarkers (94 papers), Pancreatic and Hepatic Oncology Research (63 papers) and Genetic factors in colorectal cancer (49 papers). Dung T. Le is often cited by papers focused on Cancer Immunotherapy and Biomarkers (94 papers), Pancreatic and Hepatic Oncology Research (63 papers) and Genetic factors in colorectal cancer (49 papers). Dung T. Le collaborates with scholars based in United States, Japan and United Kingdom. Dung T. Le's co-authors include Elizabeth M. Jaffee, Luis A. Díaz, James R. Eshleman, Marina Baretti, Jonathan C. Dudley, Ming‐Tseh Lin, Daniel A. Laheru, Evan J. Lipson, Patrick A. Ott and Elizabeth A. Sugar and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Dung T. Le

190 papers receiving 11.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

2016 848 citations Dung T. Le et al. profile →
Microsatellite Instability as a Biomarker for PD-1 Blockade

2016 674 citations Dung T. Le et al. Clinical Cancer Research profile →
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

2016 511 citations Padmanee Sharma, Margaret K. Callahan et al. profile →
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

2022 501 citations Luis A. Díaz, Kai‐Keen Shiu et al. profile →
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

2018 471 citations Johanna C. Bendell, Padmanee Sharma et al. Journal of Clinical Oncology profile →
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

2016 452 citations Dung T. Le, Patrick A. Ott et al. profile →
Evolutionary dynamics of cancer in response to targeted combination therapy

2013 433 citations Dung T. Le, Luis A. Díaz et al. profile →
DNA mismatch repair in cancer

2018 383 citations Dung T. Le et al. profile →
PD-1 blockade in tumors with mismatch repair deficiency.

2015 339 citations Dung T. Le, Bjarne R. Bartlett et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Dung T. Le

Since Specialization

Citations

This map shows the geographic impact of Dung T. Le's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dung T. Le with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dung T. Le more than expected).

Fields of papers citing papers by Dung T. Le

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dung T. Le. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dung T. Le. The network helps show where Dung T. Le may publish in the future.

Co-authorship network of co-authors of Dung T. Le

This figure shows the co-authorship network connecting the top 25 collaborators of Dung T. Le. A scholar is included among the top collaborators of Dung T. Le based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dung T. Le. Dung T. Le is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development and selection of candidate monoclonal antibodies for the detection of Clostridium botulinum neurotoxin serotype B light chain 2025 ·Protein Expression and Purification ·(unknown), (unknown), Holly Hoang, Hung Viet Pham, (unknown), (unknown), Dung T. Le, (unknown), Lan Anh Lé	1
2	A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer. 2024 ·Journal of Clinical Oncology ·Eric S. Christenson, Daruka Mahadevan, Syed Mohammad Ali Kazmi, Sudhir Manda, Davendra Sohal, Thomas E. Hutson, Siqing Fu, (unknown), (unknown), Emilia Alina Barbu, Dallas B. Flies, Solomon Langermann, Michael Chisamore, Martin Gutierrez, Marc Matrana, (unknown), Raymond Wadlow, (unknown), (unknown), Dung T. Le	2
3	Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032) 2024 ·Journal for ImmunoTherapy of Cancer ·Margaret K. Callahan, Asim Amin, Frederic J. Kaye, Michael A. Morse, Matthew H. Taylor, Katriina Peltola, Padmanee Sharma, Eileen M. O’Reilly, (unknown), Shaun O’Brien, Marina Tschaika, Dung T. Le	7
4	Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors 2024 ·Journal for ImmunoTherapy of Cancer ·Nikhil I. Khushalani, Patrick A. Ott, Robert L. Ferris, Tina Cascone, Dirk Schadendorf, Dung T. Le, Manish Sharma, Fabrice Barlési, William H. Sharfman, Jason J. Luke, Ignacio Melero, Deanne Lathers, Jaclyn Neely, Satyendra Suryawanshi, Abanti Sanyal, James L. Holloway, (unknown), S. Ely, Neil H. Segal	18
5	LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study 2023 ·Annals of Oncology ·(unknown), Thierry André, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, C.J.A. Punt, Denis Smith, Rocio García‐Carbonero, Julia Alcaide, Peter Gibbs, Christelle de la Fouchardière, Fernando Rivera, (unknown), Dung T. Le, Takayuki Yoshino, Yu Zuo, (unknown), David E. Adelberg, Luis A. Díaz	12
6	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer 2023 ·Journal for ImmunoTherapy of Cancer ·Ronan J. Kelly, Katherine M. Bever, Joseph Chao, Kristen K. Ciombor, Cathy Eng, Marwan Fakih, Lipika Goyal, Joleen M. Hubbard, Renuka Iyer, Holly Kemberling, Smitha Krishnamurthi, Geoffrey Y. Ku, (unknown), Van K. Morris, Andrew Scott Paulson, (unknown), Manish A. Shah, Dung T. Le	14
7	Converging on a Cure: The Roads to Predictive Immunotherapy 2023 ·Cancer Discovery ·Genevieve Stein-O’Brien, Dung T. Le, Elizabeth M. Jaffee, Elana J. Fertig, Neeha Zaidi	5
8	O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer 2021 ·Annals of Oncology ·Thierry André, Kai‐Keen Shiu, (unknown), Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J.A. Punt, Denis Smith, Rocio García‐Carbonero, Julia Alcaide, Peter Gibbs, Christelle de la Fouchardière, F. Rivera Herrero, Elena Élez, Johanna C. Bendell, Dung T. Le, Takayuki Yoshino, (unknown), David R. Fogelman, Patricia Marinello, Luis A. Díaz	1
9	Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer 2020 ·Cancer Immunology Research ·Nitya Nair, (unknown), Ed Lemmens, Serena Chang, Dung T. Le, Elizabeth M. Jaffee, Aimee Murphy, Chan C. Whiting, Thomas Müller, Dirk G. Brockstedt	17
10	A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer 2020 ·Clinical Cancer Research ·Annie A. Wu, Katherine M. Bever, Won Jin Ho, Elana J. Fertig, Nan Niu, Lei Zheng, Rose Parkinson, Jennifer N. Durham, Beth Onners, Anna Ferguson, Cara Wilt, Andrew H. Ko, Andrea Wang‐Gillam, Daniel A. Laheru, Robert A. Anders, Elizabeth D. Thompson, Elizabeth A. Sugar, Elizabeth M. Jaffee, Dung T. Le	91
11	Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy 2019 ·Cancer Immunology Research ·Nicolás J. Llosa, Brandon Luber, Nicholas Siegel, (unknown), (unknown), Qingfeng Zhu, Bjarne R. Bartlett, Laveet K. Aulakh, Elizabeth D. Thompson, Elizabeth M. Jaffee, Jennifer N. Durham, Cynthia L. Sears, Dung T. Le, Luis A. Díaz, Drew M. Pardoll, Hao Wang, Franck Housseau, Robert A. Anders	32
12	Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade 2019 ·Clinical Cancer Research ·Andrew Georgiadis, Jennifer N. Durham, Laurel A. Keefer, Bjarne R. Bartlett, (unknown), Derek Murphy, James R. White, Steve Lu, (unknown), (unknown), David R. Riley, Robert A. Anders, Erika Gedvilaite, Samuel V. Angiuoli, Siân Jones, Victor E. Velculescu, Dung T. Le, Luis A. Díaz, Mark Sausen	110
13	A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer 2019 ·Cancer Medicine ·Mark Yarchoan, Chiung‐Yu Huang, Qingfeng Zhu, Anna Ferguson, Jennifer N. Durham, Robert A. Anders, Elizabeth D. Thompson, Noah Rozich, Dwayne L. Thomas, Julie M. Nauroth, (unknown), Arsen Osipov, Ana De Jesus‐Acosta, Dung T. Le, Adrian Murphy, Daniel A. Laheru, Ross C. Donehower, Elizabeth M. Jaffee, Lei Zheng, Nilofer S. Azad	68
14	A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan 2018 ·Clinical Cancer Research ·Valerie Lee, Judy Wang, Marianna Zahurak, Elske C. Gootjes, Henk M.W. Verheul, Rose Parkinson, Zachary Kerner, Anup Sharma, Gary L. Rosner, Ana De Jesus‐Acosta, Daniel A. Laheru, Dung T. Le, Aram Oganesian, (unknown), Thomas D. Brown, Peter A. Jones, Stephen B. Baylin, Nita Ahuja, (unknown)	39
15	Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). 2017 ·Journal of Clinical Oncology ·Dung T. Le, Andrew H. Ko, Zev A. Wainberg, Vincent J. Picozzi, Hedy L. Kindler, Andrea Wang‐Gillam, Paul E. Oberstein, Michael A. Morse, Herbert J. Zeh, Colin D. Weekes, Tony R. Reid, Aimee Murphy, (unknown), Chan C. Whiting, Nitya Nair, Amanda Enstrom, Sandy Ferber, Thomas W. Dubensky, Dirk G. Brockstedt, Elizabeth M. Jaffee	39
16	Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer 2016 ·Cancer Immunology Research ·(unknown), Min‐Sik Kim, Elizabeth D. Thompson, Lanqing Huang, Rajni Sharma, Alison P. Klein, Lei Zheng, Dung T. Le, Daniel A. Laheru, Akhilesh Pandey, Elizabeth M. Jaffee, Robert A. Anders	19
17	Baseline Hemoglobin-A1c Impacts Clinical Outcomes in Patients With Pancreatic Cancer 2014 ·Journal of the National Comprehensive Cancer Network ·Katherine Fan, Avani Satish Dholakia, Aaron T. Wild, Zheng Su, Amy Hacker‐Prietz, Rachit Kumar, Mary Hodgin, Charles C. Hsu, Dung T. Le, Ana De Jesus‐Acosta, Luis A. Díaz, Daniel A. Laheru, Ralph H. Hruban, Elliot K. Fishman, (unknown), Timothy M. Pawlik, Christopher L. Wolfgang, Phuoc T. Tran, Joseph M. Herman	18
18	A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma 2011 ·Annals of Surgery ·(unknown), Charles J. Yeo, Keith D. Lillemoe, Barbara Biedrzycki, Barry Kobrin, Joseph M. Herman, Elizabeth A. Sugar, Steven Piantadosi, John L. Cameron, Sara Solt, Beth Onners, Irena Tartakovsky, Miri Choi, Rajni Sharma, Peter B. Illei, (unknown), Ross A. Abrams, Dung T. Le, Elizabeth M. Jaffee, Dan Laheru	295
19	Tyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer 2011 ·PLoS ONE ·Lei Zheng, Kelly Foley, Lanqing Huang, Ashley Leubner, Guanglan Mo, Kelly Olino, Barish H. Edil, Masamichi Mizuma, Rajni Sharma, Dung T. Le, Robert A. Anders, Peter B. Illei, Jennifer E. Van Eyk, Anirban Maitra, Daniel A. Laheru, Elizabeth M. Jaffee	156
20	Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation 2008 ·Clinical Cancer Research ·Dan Laheru, Eric R. Lutz, James M. Burke, Barbara Biedrzycki, Sara Solt, Beth Onners, Irena Tartakovsky, John Nemunaitis, Dung T. Le, Elizabeth A. Sugar, Kristen Hege, Elizabeth M. Jaffee	259

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact